These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1645517)

  • 41. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy.
    Kumlien E; Hartvig P; Valind S; Oye I; Tedroff J; Långström B
    Epilepsia; 1999 Jan; 40(1):30-7. PubMed ID: 9924899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PET imaging of opioid receptors in pain: progress and new directions.
    Ravert HT; Bencherif B; Madar I; Frost JJ
    Curr Pharm Des; 2004; 10(7):759-68. PubMed ID: 15032701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Positron emission tomography in psychiatric and neuropsychiatric disorders.
    Dolan RJ; Friston KJ
    Semin Neurol; 1989 Dec; 9(4):330-7. PubMed ID: 2701777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential brain opioid receptor availability in central and peripheral neuropathic pain.
    Maarrawi J; Peyron R; Mertens P; Costes N; Magnin M; Sindou M; Laurent B; Garcia-Larrea L
    Pain; 2007 Jan; 127(1-2):183-94. PubMed ID: 17137714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regional cerebral opioid receptor studies with [11C]diprenorphine in normal volunteers.
    Jones AK; Luthra SK; Maziere B; Pike VW; Loc'h C; Crouzel C; Syrota A; Jones T
    J Neurosci Methods; 1988 Mar; 23(2):121-9. PubMed ID: 2833666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence.
    Bencherif B; Wand GS; McCaul ME; Kim YK; Ilgin N; Dannals RF; Frost JJ
    Biol Psychiatry; 2004 Feb; 55(3):255-62. PubMed ID: 14744466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imaging of opioid receptors in the central nervous system.
    Henriksen G; Willoch F
    Brain; 2008 May; 131(Pt 5):1171-96. PubMed ID: 18048446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional neuroimaging with positron emission tomography.
    Henry TR
    Epilepsia; 1996 Dec; 37(12):1141-54. PubMed ID: 8956845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantification of human opiate receptor concentration and affinity using high and low specific activity [11C]diprenorphine and positron emission tomography.
    Sadzot B; Price JC; Mayberg HS; Douglass KH; Dannals RF; Lever JR; Ravert HT; Wilson AA; Wagner HN; Feldman MA
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):204-19. PubMed ID: 1847703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brain opioid receptor measurements by positron emission tomography in normal cycling women: relationship to luteinizing hormone pulsatility and gonadal steroid hormones.
    Smith YR; Zubieta JK; del Carmen MG; Dannals RF; Ravert HT; Zacur HA; Frost JJ
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4498-505. PubMed ID: 9851799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positron emission tomography in neuropsychiatry.
    Faulstich ME; Sullivan DC
    Invest Radiol; 1991 Feb; 26(2):184-94. PubMed ID: 2055721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography.
    Persson A; Ehrin E; Eriksson L; Farde L; Hedström CG; Litton JE; Mindus P; Sedvall G
    J Psychiatr Res; 1985; 19(4):609-22. PubMed ID: 3001301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.
    Siegel BV; Buchsbaum MS; Bunney WE; Gottschalk LA; Haier RJ; Lohr JB; Lottenberg S; Najafi A; Nuechterlein KH; Potkin SG
    Am J Psychiatry; 1993 Sep; 150(9):1325-36. PubMed ID: 8352343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PET radioligands for the dopamine D1-receptor: Application in psychiatric disorders.
    Cervenka S
    Neurosci Lett; 2019 Jan; 691():26-34. PubMed ID: 29518542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia.
    Buchsbaum MS; Hazlett EA
    Schizophr Bull; 1998; 24(3):343-64. PubMed ID: 9718628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Molecular imaging of psychiatric disorders].
    Takahashi H; Suhara T
    Nihon Rinsho; 2007 Feb; 65(2):336-41. PubMed ID: 17302281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses.
    Scott DJ; Stohler CS; Egnatuk CM; Wang H; Koeppe RA; Zubieta JK
    Arch Gen Psychiatry; 2008 Feb; 65(2):220-31. PubMed ID: 18250260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Basal opioid receptor binding is associated with differences in sensory perception in healthy human subjects: a [18F]diprenorphine PET study.
    Mueller C; Klega A; Buchholz HG; Rolke R; Magerl W; Schirrmacher R; Schirrmacher E; Birklein F; Treede RD; Schreckenberger M
    Neuroimage; 2010 Jan; 49(1):731-7. PubMed ID: 19703571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.